Technical Analysis for ZYME - Zymeworks Inc.

Grade Last Price % Change Price Change
grade A 15.9 -1.43% -0.23
ZYME closed down 1.43 percent on Friday, January 18, 2019, on 87 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Flat
See historical ZYME trend table...

Date Alert Name Type % Chg
Jan 18 Bearish Engulfing Bearish 0.00%
Jan 18 Outside Day Range Expansion 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Wide Bands Range Expansion -1.43%
Jan 17 Overbought Stochastic Strength -1.43%
Jan 16 Pocket Pivot Bullish Swing Setup -2.39%
Jan 16 Volume Surge Other -2.39%
Jan 16 Wide Bands Range Expansion -2.39%
Jan 16 Overbought Stochastic Strength -2.39%

Older signals for ZYME ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.
Is ZYME a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 29.0
52 Week Low 9.57
Average Volume 175,112
200-Day Moving Average 14.4355
50-Day Moving Average 13.6244
20-Day Moving Average 14.384
10-Day Moving Average 15.868
Average True Range 0.7883
ADX 30.09
+DI 30.8104
-DI 12.4593
Chandelier Exit (Long, 3 ATRs ) 14.3351
Chandelier Exit (Short, 3 ATRs ) 13.0849
Upper Bollinger Band 18.0954
Lower Bollinger Band 10.6726
Percent B (%b) 0.7
BandWidth 51.604561
MACD Line 0.8323
MACD Signal Line 0.6986
MACD Histogram 0.1337
Fundamentals Value
Market Cap 402.9 Million
Num Shares 25.3 Million
EPS -3.52
Price-to-Earnings (P/E) Ratio -4.52
Price-to-Sales 35.32
Price-to-Book 2.18
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.22
Resistance 3 (R3) 17.34 17.02 17.00
Resistance 2 (R2) 17.02 16.68 16.96 16.93
Resistance 1 (R1) 16.46 16.48 16.30 16.34 16.85
Pivot Point 16.14 16.14 16.06 16.08 16.14
Support 1 (S1) 15.58 15.80 15.42 15.46 14.95
Support 2 (S2) 15.26 15.60 15.20 14.87
Support 3 (S3) 14.70 15.26 14.80
Support 4 (S4) 14.58